Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Regeneron's 2025 Annual Shareholders Meeting was a governance-heavy affair, with proposals flying faster than a biotech merger rumor. Shareholders voted to elect Class I directors through 2028, ...

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and patent dispute, saying the law firm wrongly switched sides despite a conflict.

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and patent dispute, saying the law firm wrongly switched sides despite a conflict.

This week's topic is semaglutide, the popular weight loss drug that has taking the world by storm in recent years. Join our hosts and guest patient Jennifer Weber as they go over the history of ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower than the percentages reported ...

FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020.

A groundbreaking study led by researchers from Columbia Data Analytics, Bogazici University and the City University of New York (CUNY) College of Technology, has demonstrated that semaglutide, a ...

Wojcicki announced Friday that her newly formed nonprofit, TTAM Research Institute, had placed a $305 million bid for the company—significantly higher than Regeneron Pharmaceuticals' $256 ...